Jefferies upgraded Charles River (CRL) to Buy from Hold with a price target of $195, up from $142. The company’s discovery and safety assessment bookings are improving and it has “several ways to create value” via a sale of all or part of its manufacturing solutions segment, the analyst tells investors in a research note. Jefferies believes the involvement of an activist and Charles River’s ongoing strategic review limit downside in the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River, Akadeum Life Sciences announce collaboration
- Charles River price target raised to $211 from $189 at Rothschild & Co Redburn
- Charles River Labs: Stability and Long-term Value Creation Potential Amidst Short-term Challenges
- Charles River price target raised to $165 from $155 at Barclays
- Charles River Laboratories Reports Q2 2025 Earnings